Exposure–Response Relationships for Efficacy and Safety of Risankizumab in Phase II and III Trials in Psoriasis Patients

Lignende værker

• Population Pharmacokinetics of the Interleukin-23 Inhibitor Risankizumab in Subjects with Psoriasis and Crohn’s Disease: Analyses of Phase I and II Trials
  af: Suleiman, Ahmed A., et al.
  Udgivet: (2018)
• Clinical Pharmacokinetics and Pharmacodynamics of Risankizumab in Psoriasis Patients
  af: Pang, Yinuo, et al.
  Udgivet: (2019)
• Population Pharmacokinetics of Risankizumab in Healthy Volunteers and Subjects with Moderate to Severe Plaque Psoriasis: Integrated Analyses of Phase I–III Clinical Trials
  af: Suleiman, Ahmed A., et al.
  Udgivet: (2019)
• Meta‐Analyses of Clinical Efficacy of Risankizumab and Adalimumab in Chronic Plaque Psoriasis: Supporting Evidence of Risankizumab Superiority
  af: Witjes, Han, et al.
  Udgivet: (2019)
• Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
  af: Khatri, Amit, et al.
  Udgivet: (2019)